Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Elderly, postmenopausal women with breast cancer on aromatase inhibitors are at increased
risk of developing bone loss and osteoporosis. We postulate that in elderly, osteopenic
postmenopausal women who are on aromatase inhibitor therapy, bisphosphonate therapy will (1)
prevent bone loss at clinically relevant sites, such as the spine and hip and (2) decrease
bone turnover.